Biogen Inc
BIIB · NASDAQ252.07
252.07
USD7.583.10%Fecha
Tickers
Titular
Fuente
Biogen to acquire RayThera in deal valued up to $1B
SeekingAlpha
Apellis surges on $5.6B buyout deal with Biogen
SeekingAlpha
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
MarketWatch
Sage Therapeutics rejects Biogen bid, starts strategic review
SeekingAlpha
Sage sues Biogen in wake of $469M buyout offer: report
SeekingAlpha
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
MarketWatch
Drugmaker Biogen boosts profit outlook on ‘momentum’ for new drugs
MarketWatch
Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
CNBC
Sage Therapeutics’ stock dives as failed trial hits Biogen collaboration
MarketWatch
IGM Biosciences up 40% following Biogen HI-Bio buy
SeekingAlpha
Biogen inks $1.8B deal to acquire immune drug developer HI-Bio
SeekingAlpha
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
CNBC
Biogen drops controversial Alzheimer’s drug
MarketWatch
Biogen quarterly results top estimates despite complex launch of new Alzheimer’s treatment
MarketWatch
Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake
MarketWatch
Reata shareholders clear buyout deal with Biogen
SeekingAlpha
Reata Pharmaceuticals climbs as HSR waiting period for sale to Biogen expired
SeekingAlpha
Biogen in $1.5B unsecured loan facility for Reata acquisition
SeekingAlpha
Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
MarketWatch
Larimar, Design higher as they benefit from Biogen deal for Reata
SeekingAlpha
Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B
SeekingAlpha
Biogen to slash 1,000 jobs as it looks to save $700 million
MarketWatch
Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch
CNBC
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
CNBC
Movers & Shakers: Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move
MarketWatch
FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment
MarketWatch
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
CNBC